<DOC>
	<DOCNO>NCT01639703</DOCNO>
	<brief_summary>The purpose study prospectively determine diagnostic value Xenetix-CT perfusion discrimination well-differentiated hepatocellular carcinoma ( HCC ) poorly/moderately differentiate HCC , histo-pathologically proven HCC , aim cover entire liver .</brief_summary>
	<brief_title>Hepatic Xenetix-CT Perfusion</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>Subjects diagnose HCC plan surgery ( lobectomy transplantation ) within timeframe 30 day first image procedure use study surgery . Subjects undergone prior TACE ( TransArterial Chemo Embolization ) , prior RFA ( Radio Frequency Ablation ) prior SIRT ( Selected Internal Radio Therapy ) within one year inclusion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>CT perfusion</keyword>
	<keyword>Hepatocellular Carcinoma</keyword>
	<keyword>Xenetix</keyword>
	<keyword>Contrast agent</keyword>
</DOC>